Debt Financing

20/20 Biolabs (AIDX) cuts Streeterville warrant price to $2.25

AIDX

20/20 Biolabs, Inc. (Nasdaq: AIDX) reduced the exercise price of warrants held by Streeterville Capital, LLC to $2.25 a share on April 23, 2026, after secured convertible notes issued since November 2025.

Investor Chat

Scorecard

AIDXDebt
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-08
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-08
Mixed record
Investment Attractiveness: 5.4/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

Convertible: up to $570,000 secured convertible notes

By the aibio.space news desk

A federal building and U.S. courthouse
A federal building and U.S. courthouse. Photo: United States District Court for the Eastern District of Missouri, Public domain, via Wikimedia Commons. The picture shows the field, not the companies named.

20/20 Biolabs, Inc. (Nasdaq: AIDX) reduced the exercise price of its warrants held by Streeterville Capital, LLC to $2.25 per share on April 23, 2026, under a global amendment with the lender. The company disclosed the amendment in a Form 8-K filed on April 28, 2026. The amendment covers warrants issued alongside secured convertible promissory notes and series E preferred stock sold to Streeterville since November 17, 2025.

Why is this important: The lower exercise price makes the warrants cheaper to exercise and could put more common shares in the lender's hands. The earlier warrant price was $11.42 for the largest warrant. For shareholders, the reset raises dilution risk. The company may end the amendment within 90 days on two trading days' notice, and Streeterville may still exercise at $2.25 during that window.

Jonathan Cohen, the chief executive, signed the filing. In our view, the sequence of deals shows a company that has relied on one lender for money again and again. Three issuances to a single lender, each tied to a warrant, followed by a price reset, is a pattern that favors the lender. We think the board has traded future ownership for near-term cash, and the record does not show how the company plans to end that cycle.

The notes, the warrants and the reset

The 8-K describes a securities purchase agreement of November 17, 2025 with Streeterville. That agreement covers secured convertible promissory notes in an aggregate principal amount of up to $570,000, and warrants to buy a number of shares equal to $1,000,000 divided by the lower of $8.00 and the Nasdaq Price. The filing says the Nasdaq Price was $11.42 after the company's direct listing was completed on February 19, 2026.

Two notes have been issued under that agreement. The November 17, 2025 note carried a principal amount of $295,000, and the company received $250,000 for it together with a warrant for 62,500 shares at $8.00. The February 9, 2026 note carried a principal of $275,000, for the same $250,000 purchase price and a second warrant for 62,500 shares at $8.00. The company also issued Streeterville 5,000 shares of series E convertible preferred and a warrant for 3,502,627 shares at $11.42, for a purchase price of $5,000,000, on February 19, 2026.

On April 23, 2026 the parties signed the global amendment. It reduced the exercise price of all three warrants to $2.25 per share, subject to the usual adjustments. The company may terminate the amendment within 90 days, on at least two trading days' written notice, and Streeterville may exercise at $2.25 during that window. The filing does not state how many shares the warrants would issue at the new price.

The cash position and the business behind the notes

The 2025 annual report, filed on March 31, 2026, reported cash and cash equivalents of $1,025,987 at December 31, 2025. The net loss for 2025 was $3,738,821, down from $5,551,667 in 2024. Cash used in operating activities was $1,919,720 for the year.

The company sells laboratory blood tests. Its lead product, OneTest for Cancer, is a multi-cancer early detection test built mainly on a panel of protein tumor markers. The 10-K reports that OneTest for Cancer sales rose to $1,803,707 in 2025 from $323,414 in 2022. The annual report says the company's continuation as a going concern depends on revenue growth that exceeds spending increases, and on continued external financing. It names no ClinicalTrials.gov study for the test.

The next dated items are the 90-day window in which the company may end the April amendment, which runs from April 23, 2026, and the company's next periodic report. The filings give no date for a further note or warrant issue under the Streeterville agreement.

The amendment is described in the Form 8-K filed April 28, 2026. The company's business, going concern language and 2025 results are in the Form 10-K filed March 31, 2026.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.